Safety, Tolerability and Efficacy of AntiBKV as Treatment of BKV Infection in Kidney Transplant Recipients

计划入组 95 人 · 首次发布于 2023 年 3 月 15 日

Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

计划入组 20 人 · 首次发布于 2020 年 3 月 3 日

Immune Registry for BK in Kidney Transplant Recipients

计划入组 60 人 · 首次发布于 2024 年 8 月 6 日

Anti-BK polyomavirus

BK polyomavirus(Orthogon Therapeutics)

BK polyomavirus program (oral, BK virus infection)

Cambridge Antibody Technology

New Zealand

Latticon Antibody Therapeutics, Inc

United States

Novel Anti-Infective Technologies, LLC

Ipsen to Acquire Memo Therapeutics in Deal Worth Over €700 Million, Securing Phase II BK Polyomavirus Antibody Potravitug

Memo Therapeutics Demonstrates Therapeutic Antibodies Can Cross Kidney Barrier, Supporting BK Virus Treatment Approach

Kurma Partners Closes Biofund IV at €215M, Fueling European Biotech Company Creation